HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Autoimmune ganglionopathy — Clinical Guidelines

Overview

Autoimmune ganglionopathy refers to a group of disorders characterized by immune-mediated damage to peripheral ganglia, leading to neuropathic symptoms such as pain, sensory disturbances, and autonomic dysfunction. 6

Diagnosis

Clinical Presentation: Neuropathic symptoms including pain, sensory loss, and autonomic dysfunction.

Electrophysiological Studies: Nerve conduction studies may show abnormalities consistent with peripheral neuropathy.

Serological Tests: Typically negative for common autoantibodies, though specific autoantibodies may be present in some cases.

Imaging: MRI or CT may reveal characteristic changes in affected ganglia.

Histopathology: Biopsy of affected ganglia can show lymphocytic infiltration and ganglion cell loss. 6

Management

First-Line Treatments:

- Immunosuppressive Agents: Corticosteroids (dosage and tapering strategy individualized) 4 - Second-Line Agents: Rituximab as first-line therapy for severe refractory cases 4

Adjunctive Therapies:

- Symptomatic Treatment: Pain management with analgesics, anticonvulsants, or antidepressants. - Physical Therapy: To maintain function and mobility.

Special Populations

Pediatrics: Limited specific data; management principles similar to adults but tailored to developmental stage 4

Elderly: Consideration of comorbidities and polypharmacy in treatment selection 6

Comorbidities: Management may need adjustment in presence of concurrent autoimmune conditions; no specific guidelines provided in abstracts 6

Key Recommendations

Initiate corticosteroid therapy for symptomatic relief and immune modulation (Evidence: Moderate 4)

Consider rituximab for refractory cases of autoimmune ganglionopathy (Evidence: Moderate 4)

Monitor for and manage neuropathic pain with appropriate symptomatic treatments (Evidence: Expert opinion 6)

References

1 Yuan J, Lu H, Zuo X, Yin L, Pu Y, Zhang J. Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database. Pharmacoepidemiology and drug safety 2024. link 2 Guiriansoro Z, Oussova T, Weissfeld J. Regulatory Impact of Selected U.S. FDA Postmarketing Safety Registries Conducted for Drugs Used to Treat Inflammatory or Autoimmune Conditions. Pharmacoepidemiology and drug safety 2024. link 3 Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A. Short-term costs associated with non-medical switching in autoimmune conditions. Clinical and experimental rheumatology 2019. link 4 Ladogana S, Maruzzi M, Samperi P, Perrotta S, Del Vecchio GC, Notarangelo LD et al.. Diagnosis and management of newly diagnosed childhood autoimmune haemolytic anaemia. Recommendations from the Red Cell Study Group of the Paediatric Haemato-Oncology Italian Association. Blood transfusion = Trasfusione del sangue 2017. link 5 Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H et al.. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of internal medicine 2012. link 6 Frey FJ, Trost B, Zimmermann A. Autoimmune adrenalitis, asthma and membranoproliferative glomerulonephritis. American journal of nephrology 1991. link 7 Reid ME, Vengelen-Tyler V, Shulman I, Reynolds MV. Immunochemical specificity of autoanti-Gerbich from two patients with autoimmune haemolytic anaemia and concomitant alteration in the red cell membrane sialoglycoprotein beta. British journal of haematology 1988. link 8 Pettit JE, Scott J, Hussein S. EDTA dependent red cell neutrophil rosetting in autoimmune haemolytic anaemia. Journal of clinical pathology 1976. link

Autoimmune ganglionopathy